(2S,3R,4S,6R)-4-amino-2-methyl-6-[5-(11-methylindolo[2,3-b]quinolin-6-yl)pentoxy]oxan-3-ol
Compound with spectra: 1 NMR
![(2S,3R,4S,6R)-4-amino-2-methyl-6-[5-(11-methylindolo[2,3-b]quinolin-6-yl)pentoxy]oxan-3-ol](/api/compound/FQX6mZfEXvl.png?ph=true&h=300&w=458 "(2S,3R,4S,6R)-4-amino-2-methyl-6-[5-(11-methylindolo[2,3-b]quinolin-6-yl)pentoxy]oxan-3-ol")
| SpectraBase Compound ID | FQX6mZfEXvl |
|---|---|
| InChI | InChI=1S/C27H33N3O3/c1-17-19-10-4-6-12-22(19)29-27-25(17)20-11-5-7-13-23(20)30(27)14-8-3-9-15-32-24-16-21(28)26(31)18(2)33-24/h4-7,10-13,18,21,24,26,31H,3,8-9,14-16,28H2,1-2H3/t18-,21-,24+,26-/m0/s1 |
| InChIKey | APNAIAJBHBSLMG-FQANYGAVSA-N |
| Mol Weight | 447.6 g/mol |
| Molecular Formula | C27H33N3O3 |
| Exact Mass | 447.252192 g/mol |
| Enantiomer InChIKey | APNAIAJBHBSLMG-JZQMGXOISA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | DMSO-D6 |
NJAGDFBMPZRKOJ-UHFFFAOYSA-N
(2S,3R,4S,6R)-4-amino-6-[5-(6,11-dimethylindolo[2,3-b]quinolin-9-yl)oxypentoxy]-2-methyloxan-3-ol
(2S,3S,4S,6R)-4-amino-6-[5-(6,11-dimethylindolo[2,3-b]quinolin-9-yl)oxypentoxy]-2-methyloxan-3-ol
(2S,3S,4S,6R)-4-amino-6-[5-(6,11-dimethylindolo[2,3-b]quinolin-2-yl)oxypentoxy]-2-methyloxan-3-ol
(2S,3R,4S,6R)-4-amino-6-[5-(6,11-dimethylindolo[2,3-b]quinolin-2-yl)oxypentoxy]-2-methyloxan-3-ol
(2S,3S,4S,6R)-4-amino-6-[2-(6,11-dimethylindolo[2,3-b]quinolin-2-yl)oxyethoxy]-2-methyloxan-3-ol
2,9-DIMETHOXY-6,11-DIMETHYL-6H-INDOLO-[2,3-B]-QUINOLINE
N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-{[5-(2-phenylethyl)-5H-[1,2,4]triazino[5,6-b]indol-3-yl]sulfanyl}acetamide
9-methoxy-6-(2-propoxybenzyl)-6H-indolo[2,3-b]quinoxaline
| Title | Journal or Book | Year |
|---|---|---|
| 1H and13C NMR data for indolo[2,3-b]quinoline–aminoglycoside hybrids, a novel potent anticancer drug family | Magnetic Resonance in Chemistry | 2006 |